Nifekalant is a class III antiarrhythmic agent that effectively suppresses ventricular tachyarrhythmia without compromising hemodynamics. We report a case in which nifekalant was effective against refractory ventricular tachycardia (VT) during weaning from cardiopulmonary bypass (CPB). The patient was a 53-year-old man with acute myocardial ischemia and severe mitral regurgitation. He suffered from refractory VT that was resistant to amiodarone and direct current (DC) shocks. Coronary artery bypass graft and mitral annuloplasty were scheduled under general anesthesia. Before induction of CPB, sinus rhythm was maintained by a continuous infusion of amiodarone (45 mg•h
−1). The cardiac procedures performed were uneventful, but refractory VT developed during weaning from CPB. VT did not respond to the continuous infusion of amiodarone and frequent DC shocks. As a last resort, a bolus of intravenous nifekalant (1 mg•kg
−1) was administered, and his sinus rhythm eventually returned to 40 beat•min
−1 after temporary cardiac arrest for approximately 20 s. By applying atrial pacing at 90 beat•min
−1, his hemodynamics stabilized, and he was weaned from CPB smoothly. Nifekalant was continuously infused at a dose of 0.4 mg•kg
−1•h
−1, and VT did not recur. In the intensive care unit, the continuous infusion of nifekalant was gradually decreased, and amiodarone was administered orally.
Nifekalant was shown to be effective for refractory VT resistant to amiodarone and cardioversion during weaning from CPB in cardiac surgery.
View full abstract